0
Signin
countryflagUS

18889881171

AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

Oncopeptides AB (publ)

Healthcare US ONPPF

0.265USD
-(-%)

Last update at 2024-05-15T13:30:00Z

Day Range

0.270.27
LowHigh

52 Week Range

0.600.85
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -337.68000M -1421.37200M -1592.44200M -739.92000M -419.30200M
Minority interest - - - - -
Net income -337.95100M -1430.31700M -1594.69300M -740.70500M -419.44900M
Selling general administrative 84.09M 175.46M 197.66M 72.05M 55.30M
Selling and marketing expenses 58.10M 698.35M 456.53M 127.41M 51.13M
Gross profit 8.35M 65.17M 0.00000M 0.00000M 0.00000M
Reconciled depreciation 17.16M 14.99M 14.40M 4.54M 0.34M
Ebit -336.79700M -1420.42400M -1590.95700M -739.39200M -419.30000M
Ebitda -319.63600M -1405.43000M -1576.55400M -734.85200M -418.95500M
Depreciation and amortization 17.16M 14.99M 14.40M 4.54M 0.34M
Non operating income net other - - - - -
Operating income -349.35000M -1420.91700M -1591.27900M -739.39200M -419.30000M
Other operating expenses 357.70M 1539.21M 1591.28M 739.39M 419.30M
Interest expense 0.88M 0.95M 1.49M 0.53M 0.00200M
Tax provision 0.27M 8.95M 2.25M 0.79M 0.15M
Interest income 2.62M 0.49M 0.32M 0.00000M 0.00000M
Net interest income 1.73M -0.45600M -1.16300M -0.52800M -0.00200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.27M 8.95M 2.25M 0.79M 0.15M
Total revenue 8.36M 118.30M 0.00000M 0.00000M 0.00000M
Total operating expenses 357.70M 1486.09M 1591.28M 739.39M 419.30M
Cost of revenue 0.00600M 53.12M - - -
Total other income expense net 11.67M -0.45500M -1.16300M -0.52800M -0.00200M
Discontinued operations - - - - -
Net income from continuing ops -337.95100M -1430.31800M -1594.69300M -740.70500M -419.44900M
Net income applicable to common shares -337.95100M -1430.31700M -1594.69300M -740.70500M -411.11200M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 385.32M 439.38M 946.76M 993.49M 444.53M
Intangible assets - 1.41M 1.83M 2.11M -
Earning assets - - - - -
Other current assets - -0.00100M 13.69M 34.30M 7.89M
Total liab 91.03M 228.51M 369.86M 196.47M 128.70M
Total stockholder equity 294.29M 210.87M 576.90M 797.01M 315.83M
Deferred long term liab - - - - -
Other current liab 51.45M 178.60M 205.84M 77.54M 88.57M
Common stock 10.48M 8.37M 7.55M 6.16M 4.90M
Capital stock 10.48M 8.37M 7.55M 6.16M 4.90M
Retained earnings -5116.41400M -4778.46300M -3348.14600M -1753.45200M -961.91900M
Other liab - 0.01M 8.53M 23.05M 14.86M
Good will - - - - -
Other assets 21.29M 0.85M 11.80M 3.30M 0.85M
Cash 344.51M 362.19M 840.25M 926.19M 375.62M
Cash and equivalents - - - - -
Total current liabilities 85.67M 225.29M 354.40M 165.18M 113.84M
Current deferred revenue 28.06M 128.68M 197.46M 77.35M -
Net debt -334.97300M -347.99400M -820.90000M -919.53400M -375.61700M
Short term debt 6.00M 10.99M 12.43M 6.65M -
Short long term debt - - - - -
Short long term debt total 9.54M 14.19M 19.36M 6.65M -
Other stockholder equity 5400.23M 4980.97M 3917.49M 2544.31M 1272.85M
Property plant equipment - 24.74M 38.33M 17.19M 2.36M
Total current assets 364.03M 412.37M 894.80M 970.89M 441.32M
Long term investments - - - - -
Net tangible assets 294.29M 209.46M 575.07M 794.90M 265.00M
Short term investments - - - - -
Net receivables 0.67M 35.89M 11.00M 6.98M 2.46M
Long term debt - - - - -
Inventory 0.00000M 0.00000M 8.66M - -
Accounts payable 28.22M 35.70M 136.13M 80.99M 25.27M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.85M 0.85M 3.62M 1.03M 0.85M
Deferred long term asset charges - - - - -
Non current assets total 21.29M 27.00M 51.96M 22.60M 3.21M
Capital lease obligations 9.54M 14.19M 19.36M 6.65M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.50700M -0.33900M -3.13100M -3.13100M -0.80000M
Change to liabilities 0.00000M -104.91100M 55.15M 55.72M 9.59M
Total cashflows from investing activities -2.50700M -0.33900M -20.12700M -2.62800M -0.90700M
Net borrowings - -15.40500M -14.26000M -3.95600M -3.95600M
Total cash from financing activities 392.40M 1034.03M 1323.46M 1236.29M 304.89M
Change to operating activities -109.23300M 42.49M 95.30M 32.95M 23.69M
Net income -349.35000M -1420.91700M -1591.27900M -739.39200M -419.30000M
Change in cash -17.67200M -478.06800M -85.93100M 550.57M -28.43300M
Begin period cash flow 362.19M 840.25M 926.19M 375.62M 404.05M
End period cash flow 344.51M 362.19M 840.25M 926.19M 375.62M
Total cash from operating activities -420.50900M -1516.39100M -1296.50900M -690.56600M -333.72700M
Issuance of capital stock 435.61M 1116.49M 1422.95M 1316.84M 324.28M
Depreciation 17.16M 14.99M 14.40M 4.54M 0.34M
Other cashflows from investing activities -2.50700M -0.33900M 0.18M 0.18M 0.26M
Dividends paid - - - - -
Change to inventory 0.00000M -0.31900M -0.42900M -0.42900M -0.42900M
Change to account receivables - 24.66M -7.74700M -29.96200M -0.76900M
Sale purchase of stock - - - - -
Other cashflows from financing activities -43.20900M -82.45800M -85.23100M -76.59500M -19.39000M
Change to netincome 26.68M -62.98600M 141.51M -13.10000M 44.53M
Capital expenditures 2.51M 0.34M 17.18M 2.63M 0.37M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -109.23300M -38.08200M 142.27M 58.70M 40.85M
Stock based compensation - - - 32.49M 12.37M
Other non cash items 20.91M -72.38600M 138.10M -46.90600M 32.01M
Free cash flow -423.01600M -1516.73000M -1313.68900M -693.19400M -334.09600M

Fundamentals

  • Previous Close 0.27
  • Market Cap67.99M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM30.44M
  • Revenue Per Share TTM0.34
  • Gross Profit TTM 8.35M
  • Diluted EPS TTM-0.28

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ONPPF
Oncopeptides AB (publ)		 - -% 0.27 - - 2.26 4.13 1.83 -0.2136
NVO
Novo Nordisk A/S		 -1.63 1.21% 133.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.57 0.43% 132.69 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.20 0.27% 438.69 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.03 1.09% 96.00 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden

Oncopeptides AB (publ)

Vastra Tradgardsgatan 15, Stockholm, Sweden, 111 53

Key Executives

Name Title Year Born
Dr. Jakob Lindberg Med. Lic Chief Exec. Officer 1972
Prof. Rolf Larsson M.D., Ph.D. Founder NA
Prof. Rolf Lewensohn M.D., Ph.D. Founder NA
Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. Founder NA
Dr. Kristina Luthman Ph.D. Founder NA
Prof. Hans Ehrsson M.D. Founder NA
Mr. Peter Nygren Founder 1959
Ms. Annika Muskantor M.B.A. Interim Chief Financial Officer 1966
Ms. Eva Nordström M.Sc., MSc Pharm COO & Deputy MD 1970
Ms. Linda Holmstrom Director of Investor Relations NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).